ABEONA THERAPEUTICS INC. Capital Expenditures Incurred but Not yet Paid
ABEONA THERAPEUTICS INC. (ABEO) reported Capital Expenditures Incurred but Not yet Paid of $301.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2025-11-12
- ABEONA THERAPEUTICS INC. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was -$1.06M.
- ABEONA THERAPEUTICS INC. capital expenditures incurred but not yet paid for the quarter ending 2025-06-30 was $185.00K.
- ABEONA THERAPEUTICS INC. capital expenditures incurred but not yet paid for the quarter ending 2025-03-31 was $1.18M.
- ABEONA THERAPEUTICS INC. capital expenditures incurred but not yet paid for the quarter ending 2024-12-31 was $305.00K.
- ABEONA THERAPEUTICS INC. capital expenditures incurred but not yet paid for fiscal 2024 was $471.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2025-09-30 | -$1.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$878.00K derived: sum of 2 quarters · filed 2025-11-12 | $301.00K 10-Q · filed 2025-11-12 | $606.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | $185.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $1.36M 10-Q · filed 2025-08-14 | $1.67M derived: sum of 3 quarters · filed 2025-08-14 | |
| 2025-03-31 | $1.18M 10-Q · filed 2025-05-15 | $1.48M derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2024-12-31 | $305.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $471.00K 10-K · filed 2025-03-20 | ||
| 2024-09-30 | $166.00K 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |